Atlanpole Biotherapies presents its strategic priorities

5 April 2018

At its annual meeting , the Atlanpole Biotherapies western France biocluster presented its 2017 business report and outlook for 2018. While the cluster’s primary areas of focus since its foundation—immunotherapy, regenerative medicine, and radiopharmaceuticals, all relying on scientific excellence at an international scale—remain central, the multidisciplinary fields of e-health and P4 medicine are new strategic issues for 2018.

Press Release